ReviewMyocarditis Following COVID-19 Vaccination: A Systematic Review (October 2020–October 2021)
Introduction
As the pandemic caused by the SARS-CoV-2 coronavirus (COVID-19) continues, global efforts driving vaccinations are pivotal to restoring health and attempting economic and social recovery. In December 2020, the USA Food and Drug Administration (FDA) granted emergency authorisation for the Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1273) COVID-19 vaccines. In recent months, reports of myocarditis following COVID-19 vaccination, particularly after the messenger RNA (mRNA) vaccines, have received media publicity and raised concerns amongst the general public.
There is a pressing need for a better understanding of the available data, especially as several countries debate vaccination of adolescents in light of the concerns from the Omicron variant. This report reviews the current literature regarding myocarditis post COVID-19 vaccination, summarising both publicly available information from vaccine safety surveillance databases and published case reports, with particular attention to reporting rates, patient and disease characteristics, as well as investigation and treatment outcomes.
Section snippets
Methods
This review performed systematic searches of online databases, including PubMed and two COVID-19-specific databases (LitCovid [1] and the Cochrane COVID-19 Study Register) between 1 October 2020 and 31 October 2021. LitCovid was selected as a curated literature repository for articles on COVID-19 from PubMed [2]. The Cochrane COVID-19 Study Register was selected for comprehensiveness and accuracy, with multiple data sources cited, including PubMed and Embase.com [3]. The medical subjects
Vaccine Safety Surveillance Databases
The most commonly referenced vaccine safety surveillance databases were selected, these were: the World Health Organization (WHO) global database VigiBase [4], the USA Vaccine Adverse Event Reporting System (VAERS) [5], the UK Medicines and Healthcare Regulatory Agency (MHRA), and information from the Israeli Ministry of Health. These countries are amongst those that had relatively early and large-scale vaccination drives. Data from the Health Sciences Authority (HSA) of Singapore from the
Discussion
The reports of myocarditis post COVID-19 vaccines, particularly with mRNA vaccines, are a public safety concern. Myocarditis itself is usually idiopathic. If an identified cause is found, it is usually viral in aetiology [43]. Vaccine-related myocarditis is rare, with previous cases associated with the smallpox [44,45] and influenza [46,47] vaccines. The original clinical trials for these mRNA vaccines did not detect myocarditis [48,49], although there was one case of paroxysmal ventricular
Conclusion
As countries debate vaccination of younger adolescents and children, the public and healthcare professionals should be aware of the symptoms associated with COVID-19 vaccine-related myocarditis, but also that the overall risk appears low. However, further research into this condition is warranted, particularly regarding the pathogenesis and higher prevalence in younger males. There is also a current gap in understanding in a few population groups, including those aged <16 years, those with
Declarations of interest
None.
Funding sources
Nil.
References (65)
- et al.
Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations
J Am Coll Cardiol
(2018) - et al.
Keep up with the latest coronavirus research
Nature
(2020) - et al.
LitCovid: An open database of COVID-19 literature
Nucleic Acids Res
(2021) - et al.
Evaluation of the comprehensiveness, accuracy and currency of the Cochrane COVID-19 Study Register for supporting rapid evidence synthesis production
Res Synth Methods
(2021) VigiBase, the WHO Global ICSR Database System: Basic facts
Drug Inf J
(2008)- et al.
Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)
Vaccine
(2015) - et al.
COVID-19 vaccines and myocarditis
Arch Cardiovasc Dis
(2021) - et al.
Acute myocardial injury following COVID-19 vaccination : a case report and review of current evidence from Vaccine Adverse Events Reporting System Database
J Prim Care Community Health
(2021) - et al.
Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the Advisory Committee on Immunization Practices
MMWR Morb Mortal Wkly Rep
(2021) - et al.
Use of COVID-19 vaccines after reports of adverse events among adult recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021
MMWR Morb Mortal Wkly Rep
(2021)
Coronavirus vaccine - weekly summary of Yellow Card reporting. Med Healthc Prod Regul Agency
COVID-19 vaccines: updates for July 2021. Med Healthc Prod Regul Agency
Surveillance of myocarditis (inflammation of the heart muscle) cases between December 2020 and May 2021 (Including)
Pericarditis tras la administración de la vacuna de ARNm BNT162b2 contra la COVID-19
Rev Española Cardiol
Myocarditis and other cardiovascular complications of the mRNA-based COVID-19 vaccines
Cureus
A case report: symptomatic pericarditis post-COVID-19 vaccination
Eur Hear J Case Rep
Acute myopericarditis after COVID-19 vaccine in teenagers
Case Rep Cardiol
Myopericarditis after the Pfizer messenger ribonucleic acid Coronavirus disease vaccine in adolescents
J Pediatr
Association of myocarditis with BNT162b2 messenger RNA COVID-19 vaccine in a case series of children
JAMA Cardiol
Myocarditis and pericarditis following mRNA COVID-19 vaccination: what do we know so far?
Child
Myocarditis following immunization with mRNA COVID-19 vaccines in members of the US Military
JAMA Cardiol
Myocarditis following COVID-19 vaccination – A case series
Vaccine
A late presentation of COVID-19 vaccine-induced myocarditis
Cureus
Myocarditis temporally associated with COVID-19 vaccination
Circulation
COVID-19 vaccine-induced myocarditis: case report with literature review
Diabetes Metab Syndr
Temporal association between the COVID-19 Ad26.COV2.S vaccine and acute myocarditis: A case report and literature review
Cardiovasc Revasc Med
Occurrence of acute infarct-like myocarditis following COVID-19 vaccination: just an accidental co-incidence or rather vaccination-associated autoimmune myocarditis?
Clin Res Cardiol
Possible association between COVID-19 vaccine and myocarditis: clinical and CMR findings
JACC Cardiovasc Imaging
A series of patients with myocarditis following SARS-CoV-2 vaccination with mRNA-1279 and BNT162b2
JACC Cardiovasc Imaging
Myocarditis after BNT162b2 and mRNA-1273 vaccination
Circulation
Myocarditis after Covid-19 mRNA vaccination
N Engl J Med
Cited by (17)
Immunogenicity and safety of heterologous mRNA-1273/MVC-COV1901 vaccination versus homologous mRNA1273 vaccination: A randomized, double-blind controlled study
2023, Journal of the Formosan Medical AssociationBNT162b2 immunization-related myocarditis in adolescents and consequent hospitalization: Report from a medical center
2023, Pediatrics and NeonatologyComparative Risk of Myocarditis/Pericarditis Following Second Doses of BNT162b2 and mRNA-1273 Coronavirus Vaccines
2022, Journal of the American College of CardiologyGlobal reports of myocarditis following COVID-19 vaccination: A systematic review and meta-analysis
2022, Diabetes and Metabolic Syndrome: Clinical Research and ReviewsCitation Excerpt :Cardiac-specific investigations revealed that troponin levels were elevated in almost all cases, consistent with myocardial injury, which is associated with autoimmune processes matched with vaccine protein and the case immune system. In the same lines as Lee et al. (2022) [1], a systematic review to investigate myocarditis following COVID-19 Vaccination in October 2020–October 2021, mentions that all reported cases have an elevated troponin level in keeping with myocardial injury. In our study, less than one third of cases had left ventricle ejection fraction (LVEF) was less than 50%.
Anti-GAD antibody-positive fulminant type 1 diabetes developed following SARS-CoV-2 vaccination
2023, Diabetology International